**Liverpool LPC – CATC and PSNC targets – 16th March 2021**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Name** | **Designation** |  | **Members** |
|  | Gemma Whitehead (GW) | Member / Chair | ✓ |
|  | Anna Mir (AM) | Member / Vice Chair | x |
|  | James Forshaw (JF) | Member / Treasurer | ✓ |
|  | Dave Sanchez (DS) | Member | ✓ |
|  | James Moir (JM) | Member | ✓ |
|  | David Porter (DP) | Member | ✓ |
|  | John Davey (JD) | Member | ✓ |
|  | Leah Davies (LD) | Member | ✓ |
|  | Peter Beeley (PB) | Member | ✓ |
|  | Dave Jones (DJ) | Member | ✓ |
|  | Matt Harvey (MH) | Chief Officer | ✓ |
|  | David Barker (DB) | Engagement Officer | ✓ |
|  | Thomas Wareing (TW) | Business Support Officer | x |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |

|  |  |
| --- | --- |
| **1** | Discussion on the new budget proposalMH gave an overview of the discussions he had been having with NHSE&I and Liverpool CCG since the last LPC meeting. NHSE&I have proposed to increase the total Care at the Chemist envelope to £600K, with £100K of that amount to be transferred to the CCG for the Pharmacy First service. This ensures that Care at the Chemist funding is not reduced based on 2020/21 spend.**Vote:** Committee members voted unanimously in favour of this. |
| **2** | Discussion over the efficiency savingsMH had also been looking through the formulary to see whether there were any tweaks that could be made to free up funds for an expansion of the service. The review also looked at NICE CKS guidance to ensure the products that remained were those that are recommended.Proposals included:* Revert pain relief items back to Drug Tariff pricing. **Vote:** Members voted unanimously.
* Remove Gaviscon but leave Acidex available. **Vote:** Members voted unanimously.
* Remove Loperamide. **Vote:** Members disagreed.
* Remove Pholcodeine. **Vote:** Members voted unanimously.

Members also recommended removing Ranitidine from the formulary as not available currently and to prevent any cost pressure if it came back. |

|  |  |
| --- | --- |
| **3** | Care at the Chemist PlusMH has been having discussions with NHSE and the CCG around expanding the protocols and formulary of Care at the Chemist but only for CPCS consultations. Members were happy with this and listed the following treatments/conditions that might be included:* Ear Calm Spray (currently 2nd line Pan Mersey)
* Hyoscine
* Esomeprazole
* Dry eye treatment
* Difflam Spray (many OOH scripts for this)
* Magnesium Sulphate Paste
* Impetigo treatment (would be a PGD)
* Nystatin in addition to miconazole

Members also branched out to discussions of other long-term condition treatments, including spacer devices for those with respiratory conditions, blood pressure management and inhaler technique. It was deemed these items fall outside of the acute treatment episode nature of Care at the Chemist, but MH can take these away and work up proposals. JD also detailed a funding bid invitation he had been sent over blood pressure.  JD will send this over to MH to see whether a bid is feasible. |
| **4** | PSNC Chairs and Chief Officer’s meetingPSNC are holding a LPC meeting on 17th March 2021. Ahead of the event, they asked for LPCs to come up with their top five priorities and enablers for the year ahead, so that these are ready to share for discussion in the breakout groups.  Members came up with the following for MH and GW to report back:* PCN Leads and Clinical Directors attending meetings regularly together.
* Ensure enough pharmacists on boards of ICS etc, to not dilute the voice of pharmacy on these.
* Embed ourselves and work collaboratively with upper echelons of NHSE local team.
* Continue to collaborate as 4 LPCs and share workstreams more closely.
* Developing services to be fit for the future and adapts with new NHS ways of working.
 |